Approved for In combination with fulvestrant, to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation following progression on endocrine therapy in the metastatic setting. 12.1 Mechanism of Action Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream…
Loading full data from Know Your Drugs Institute…